The Global Ventricular Tachycardia Market is estimated to be valued at USD 15.52 Bn in 2025 and is expected to reach USD 22.28 Bn by 2032, reflecting a compound annual growth rate (CAGR) of 5.3% from ...

FineHeart announced that it completed the $40.7 million first closing of its Series C financing round to support its heart ...

The clinic will be able to accommodate 1,500 patients over a long period and 50 patients with a left ventricular assist ...

Patients with pre-existing high blood pressure are more likely to be susceptible to heart damage caused by anthracyclines, the most widely used chemotherapy drugs for cancer treatment for more than 30 ...

Preliminary results from the FULCRUM-VT trial point to a safer, more effective way to treat ventricular tachycardia—a dangerous heart rhythm disorder that can lead to sudden cardiac arrest.

Higher baseline serum magnesium levels are linked to a higher risk for cardiac events in HFmrEF/HFpEF, while empagliflozin treatment shows a lower risk for these events in those with higher magnesium.

AliveCor, the global leader in AI-powered cardiology, today announced it has received U.S. Food and Drug Administration (FDA) ...

Professional cardiology societies have issued an updated guideline for the management of adult patients with congenital heart ...

Duchenne: Dosed 33 participants in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of January 9, 2026; SGT-003 continues to be generally well ...

While the manner of death can medically be classified as “natural,” the circumstances leading up to Russell’s death were entirely preventable.

Secondary US filings for Bayer assets cannot be relied on again to face future patent cliffs, demanding focus on early-stage R&D.